# Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer

> **NCT00585377** · PHASE2 · COMPLETED · sponsor: **University of Utah** · enrollment: 50 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Bevacizumab and Erlotinib

## Key facts

- **NCT ID:** NCT00585377
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2015-09-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00585377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00585377, "Bevacizumab (Avastin®) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00585377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*